Novavax Inc. has delayed plans to seek regulatory clearances for its COVID-19 vaccine, while shortages in raw materials are slowing the ramp-up of production of doses, the company said.
Epic’s main economic expert, David Evans, chairman of Global Economics Group, detailed Apple’s monopoly in smartphone operating systems as the relevant market in question.
There is now an authorized COVID-19 vaccine for younger teens, paving the way for immunizations to begin to reach a broader group of Americans at a time when the pace of vaccinations is slowing.